Skip to content

Zevra Therapeutics, Inc. ZVRA Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$37.89M+211%$12.17M+2,336%-$544K-101%$74.71M+2,511%-$3.1M+91.3%
$368K+1.7%$362K-7.7%$392K-76.3%$1.65M+0.1%$1.65M+0.1%
$3.11M-27.5%$4.28M+54.6%$2.77M+12.5%$2.46M-20.9%$3.12M-22.5%
$6.14M-$3.6M+56.2%-$8.22M+49.4%
$35K$0-100%$554K+160%$213K+115%$99K
$79.62M+34,974%$227K$11.93M+13.2%$10.54M+293%
$60.09M$0$0$0$0
-$52.8M-2,174%$2.55M-61.0%$6.53M+373%$1.38M-14.1%$1.61M+102%
$33.19M+317%$7.97M+18.4%$6.73M-35.1%$10.37M+192%$3.56M+118%
$6.11M-$3.81M+54.2%-$8.32M+48.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Zevra Therapeutics, Inc. generate?
Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
What is Zevra Therapeutics, Inc.'s free cash flow?
After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
Where does Zevra Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.